| Title: | Critical Therapeutics, Inc |
| Price: | $100.00 |
| Publication Date: | May 19, 2008 |
| Abstract: | Datamonitor's Critical Therapeutics, Inc Company Profile is the essential source for top-level company data and information. The report examines the company's key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy.
Critical Therapeutics is a biopharmaceutical company engaged in the development and commercialization of products for respiratory, inflammatory and critical care diseases. The company owns worldwide rights to two FDA approved drugs for the prevention and chronic treatment of asthma in patients 12 years of age and older: twice-daily ZYFLO CR (zileuton) extended-release tablets and ZYFLO (zileuton tablets). It is headquartered in Lexington, Massechusetts and employs about 60 people. The company recorded revenues of $12.9 million during the fiscal year ended December 2007, a decrease of 1.6% over 2006. The operating loss of the company was $38.8 million during fiscal year 2007, as compared to an operating loss of $51.3 million in 2006. The net loss was $37 million in fiscal year 2007, as compared to the net loss of $48.8 million in 2006. http://phx.corporate-ir.net/phoenix.zhtml?c=177530&p=irol-newsArticle&ID=1122781&highlight=
Scope of the Report
- Provides all the crucial company information required for business and competitor intelligence needs
- Data is supplemented with details on the company's history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available company statement.
Reasons to Purchase
- Support sales activities by understanding your customers' businesses better
- Qualify prospective partners and suppliers
- Keep fully up to date on your competitors' business structure, strategy and prospects
- Obtain the most up to date company information available |
| Brief Excerpt: | ...Critical Therapeutics is a biophar maceutical compan y engaged in the de velopment and commercialization of products f or respir atory, inflammator y and cr itical care diseases .The compan yowns w orldwide r ights to tw o FD A appro ved dr ugs f or the pre vention and chronic treatment of asthma in patients ## y ears of age and older : twice-daily ZYFLO CR (zileuton) e xtended-release tab lets and ZYFLO (zileuton tab lets). It is headquar tered in Le xington, Massechusetts and emplo ys about ## people.The compan y recorded re venues of $##.# million dur ing the fiscal y ear ended December ####, as compared to $#.# million in ####. The oper ating loss of the compan y w as $##.# million dur ing fiscal year ####, as compared to a oper ating loss of $##.# million in ####. The net loss w as $##.# million in fiscal y ear ####, as compared to a net loss of $##.# million in ####. ... |
| Word Count: | 6819 |
| Length: | 20 Pages |
| Format: | 
Adobe Acrobat
|
| Free Sample: |
Click
Here
to Download
|
Looking For Something Else?
